Audax Medical Inc. entered into partnership deal with Brown University for a nanotechnology-based biomaterial for regenerative medicine.
The licensing agreement gives the Littleton, Massachusetts-based company exclusive rights to Arxis, which is based on an organic osteobiologic developed at the university’s School of Engineering and Dept. of Orthopedics.
Audax and Brown also signed a deal for further research on the technology to support its clinical development, according to the company. The company said Arxis has a potential for regenerative treatments throughout the musculoskeletal system. According to the company’s website, the material is being designed as an injection for “optimizing spine-specific osteogenic biomaterials for improved bone-biomaterial cohesion.”
Health Benefit Consultants, Share Your Expert Insights in Our Survey
MassDevice Staff Website The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
“Our partnership with Brown and the university’s world-class scientific team is a significant milestone for Audax… The addition of this technology to the company’s product portfolio greatly expands our growing regenerative osteobiologics and soft tissue platforms,” said CEO Mark Johanson in prepared remarks.
In June, Audux pulled in just more than $686,000 in a pair of equity offerings, according to filings with the Securities & Exchange Commission. The company raised an initial $551,000 May 6 and another $135,000 May 27, according to the filings.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
